Transcenta Group receives milestone payment from HiCB out-license; CDMO business grows steadily

Princeton, New Jersey, USA and Suzhou, China – May 26, 2026 – Transcenta Holdings Limited (HKEX: 06628), a clinical-stage global biopharmaceutical company with integrated capabilities across biologic drug discovery, development, process development, and manufacturing, announced it has received a RMB 7 million milestone payment from the out-licensing of its HiCB (Highly Integrated Continuous Bioprocessing) platform, alongside significant progress in its CDMO business.

Following the strategic collaboration and non-exclusive technology license agreement signed with EirGenix Inc. (“EirGenix”) (TWSE: 6589) at the end of 2025 and receipt of the associated upfront payment, both companies have now achieved a major technical milestone, triggering the first milestone payment. To date, Transcenta has successfully fulfilled key deliverables under the agreement. The collaboration is progressing steadily, with the goal of implementing HiCB technology for GMP manufacturing at EirGenix’s facilities.

To further advance the commercialization of the HiCB platform, Transcenta recently appointed its former Chief Technology Officer (CTO), Dr. Guangcheng Huang, as Head of Global Partnerships for the HiCB platform. Dr. Huang will lead the global strategy and execution of the platform’s out-licensing initiatives. Under his leadership, Transcenta will continue to expand this non-exclusive licensing model, which allows the company to retain full ownership of the technology while generating revenue through licensing fees, customized CHO media optimization services, and ongoing media supply. Proceeds will be reinvested into platform enhancements and core pipeline development.

Meanwhile, Transcenta’s CDMO business continues to make steady progress. The company has recently signed new service agreements to use its HiCB process for GMP drug substance (DS) manufacturing of complex biologics and GMP drug product (DP) manufacturing for siRNA programs. Transcenta is currently in discussions on additional high-potential projects, including integrated IND-enabling development programs, siRNA GMP drug product manufacturing, developability assessments, and material production for global clients.

With advancing progress in HiCB out-licensing and continued expansion of its CDMO business, Transcenta remains well-positioned to drive sustainable growth and create long-term value for its partners and shareholders.

About Transcenta Group

Transcenta Group is a clinical-stage biopharmaceutical company with comprehensive capabilities in biologic drug discovery, research and development, process development, and manufacturing.

Transcent Group is headquartered in Suzhou and has successfully established a global business presence: it operates drug discovery, clinical, and translational research centers in Suzhou, a process and product development center as well as a drug manufacturing base in Hangzhou, and clinical development centers in China, the United States, and Europe. Transcent Group is developing a diversified pipeline that includes dozens of novel biologics covering oncology and non-oncology indications, including orthopedics, autoimmune diseases, and kidney disorders.

For more information about Transcenta, please visit the company website at www.transcenta.com or its LinkedIn page: Transcenta Therapeutics. If you are interested in exploring potential capital partnerships with us, please contact us at ir@transcenta.com to discuss collaboration opportunities.

12K Views